SCHEMBL27166104

SCHEMBL27166104

N#CC(=C1CCN(C(=O)N2CCCCC2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
AKR1C3 P42330 2/20 0.50
HPGD P15428 2/20 0.50
HTT P42858 1/20 0.50
PROKR1 Q8TCW9 4/20 0.47
POLB P06746 1/20 0.46
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 3/20 0.40
HSD11B1 P28845 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 1/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
LIPE Q05469 1/20 0.39
CHRNA7 P36544 1/20 0.39
USP2 O75604 1/20 0.39
MEN1 O00255 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29205166 0.87 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNAAKR1C3HPGD
SCHEMBL29205172 0.87 AKR1C3 (0.59) ALDH1A1SMN1; SMN2LMNAAKR1C3HPGD
SCHEMBL29205157 0.86 ALOX5 (0.44) ALDH1A1SMN1; SMN2HPGDPOLBHSD17B10
SCHEMBL27166033 0.86 PROKR1 (0.44) AKR1C3PROKR1HSD11B1MAPTMEN1
SCHEMBL29205127 0.85 ALOX5 (0.42) ALDH1A1SMN1; SMN2AKR1C3HPGDPOLB
SCHEMBL27166031 0.83 ALOX5 (0.48) AKR1C3PROKR1MAPTMEN1KMT2A
SCHEMBL27166109 0.82 PROKR1 (0.44) AKR1C3PROKR1MAPTMEN1KMT2A
SCHEMBL27166130 0.82 PROKR1 (0.45) PROKR1HSD11B1MAPT
SCHEMBL27166066 0.81 PROKR1 (0.45) LMNAAKR1C3PROKR1MAPTMEN1
SCHEMBL27166193 0.81 PROKR1 (0.43) AKR1C3PROKR1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof ORGANON R&D FINLAND LTD. (FI) 2026-05-26 US disclosed
EP-4334289-B1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Oy (FI) 2025-06-25 EP disclosed
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF ORGANON R&D FINLAND LTD. (FI) 2024-08-01 US disclosed
CN-117794899-A Novel heterocyclic compounds, compositions, methods of preparation and uses thereof 欧加农研发芬兰有限公司 2024-03-29 CN disclosed
EP-4334289-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Ltd (FI) 2024-03-13 EP disclosed
WO-2022234193-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF FORENDO PHARMA LTD (FI) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF AKR1C3, AKR1C4, AKR1C1 ALDH1A1 107/4885SMN1; SMN2 4802/4885LMNA 1565/4885
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof AKR1C3, AKR1C4, AKR1C2 ALDH1A1 100/4885SMN1; SMN2 4722/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.